Speakers discuss AI ROI in healthcare, Ennoble Care's profitable home care model, and the rising IPO revenue bar.
Summary
Christina Farr and Stephanie David analyze the healthcare sector, noting that while AI adoption is widespread, many firms lack clear ROI, whereas incumbents with clean data hold an advantage. They highlight the $5.8B acquisition of Option Care Health as evidence of distributor interest in home infusion. Kush Das and Molly Viscardi of Ennoble Care describe their profitable, human-centric home-based primary care and hospice model, which they grew to 50,000 patients through organic expansion and tuck-in acquisitions. Jordan Kohnstam and Sameer Khambadkone of ICR Healthcare warn that the IPO bar has risen to $300M-$500M in revenue with profitability, rejecting subscale or unprofitable companies. The hosts emphasize that physical logistics and high-touch care remain difficult to disrupt by AI.
Key takeaways
- 1 Healthcare runs on inefficiency and friction, meaning agentic AI, which reduces friction, poses a threat to business models profiting from these inefficiencies.
Christina Farr · 8:47
Episode sections
- 0:42 – 4:15
AI in Healthcare: Adoption, ROI, and Incumbent Advantage
Christina Farr and Stephanie David discuss takeaways from the Second Opinion Summit, noting that while AI adoption is widespread, many companies are spending millions on token usage without clear ROI. They highlight that incumbents with clean data sets have a significant advantage over unproven startups in deploying AI effectively.
- 4:15 – 14:46
Agentic AI Disruption and Home Infusion M&A
The hosts analyze how agentic AI could disrupt healthcare business models built on friction, such as subscription services and care navigation. They also discuss Option Care Health's $5.8B acquisition by Cencora and McKesson, viewing it as a strategic move into the growing home infusion market driven by demographic trends.
- 14:46 – 20:10
Ennoble Care: Mission, Background, and Growth Model
Kush Das and Molly Viscardi of Ennoble Care describe their background in emergency services and nursing, which led them to build a profitable home-based primary care and hospice business. They detail their growth to 50,000 patients across 17 states through a mix of organic expansion and tuck-in acquisitions, emphasizing a high-touch, human-centric model.
- 20:10 – 28:53
Value-Based Care: Critique of Past Models and Unit Economics
The Ennoble Care founders critique previous value-based care attempts as 'vaporware' that relied on unsustainable customer acquisition costs. They explain their profitability through operational efficiency, strong unit economics, and a focus on delivering care that reduces system-wide costs, allowing them to self-fund 40% annual growth.
- 28:53 – 35:52
Ennoble Care Operations and Hospice Economics
Kush Das describes Ennoble Care's model of employing clinicians directly to provide home-based primary care and hospice, emphasizing high-touch patient integration. He highlights that hospice care significantly reduces Medicare readmission rates compared to standard care and saves money for the Medicare trust fund.
- 35:52 – 47:34
ICR Healthcare on IPO Market Dynamics and Valuation
Jordan Kohnstam and Sameer Khambadkone discuss the shifting IPO bar, noting that companies now need $300M-$500M in revenue with profitability to attract investors. They warn against gaming sector classifications and emphasize that subscale companies are being rejected by the market.
- 47:34 – 56:46
Red Flags and Strengths in Healthcare Services
The ICR team identifies key flaws in healthcare services companies, including single-customer revenue concentration, poor utilization management in Medicare Advantage, and lack of focus. They praise specialized value-based care models that address specific, high-cost patient niches like end-of-life care.
- 56:46 – 58:35
Investment Philosophy and AthenaHealth Example
Stephanie David discusses her investment approach, prioritizing founder anti-fragility and management's ability to iterate over specific business models like value-based care or AI. She cites AthenaHealth as a positive example of a company that pivoted from women's health provider to EHR software, demonstrating resilience and market responsiveness.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| NVIDIANVDA | equity | neutral | The first one is that NVIDIA just bought a stake in a number of French tech startups, um, including a company called Doctor Lib. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Many healthcare companies have spent millions of dollars on token usage for AI without any clear ROI.
Christina Farr ·2:08
How to verify: Review earnings calls or investor presentations of major healthcare companies for AI-related expenses; search for industry reports on AI ROI in healthcare post-2026. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceAnthropic is partnering with drug makers to test AI in drug discovery.
Christina Farr ·5:09
How to verify: Search for press releases from Anthropic and major pharmaceutical companies announcing partnerships in drug discovery. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
The XBI biotech index is up over 25% year-to-date.
Stephanie David ·6:31
How to verify: Check the performance of the SPDR S&P Biotech ETF (XBI) for the period 2026-01-01 to 2026-11-12. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Option Care Health agreed to a $5.8 billion acquisition by Cencora and McKesson at $32.05 per share.
Christina Farr ·11:23
How to verify: Review press releases from Cencora and McKesson regarding the acquisition of Option Care Health; check SEC filings for the transaction details. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceEnnoble Care serves 50,000 patients across 17 states.
Unidentified speaker (UNKNOWN) ·23:42
How to verify: Check Ennoble Care's website, press releases, or investor presentations for patient count and state coverage. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Ennoble Care has completed 17 tuck-in acquisitions over the last five years.
Unidentified speaker (speaker_2) ·24:30
How to verify: Check Ennoble Care's press releases or investor presentations listing acquisition history. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Life MD had 84% of its revenues coming from recurring subscriptions.
Stephanie David ·9:41
How to verify: Review Life MD's SEC filings (10-K or 10-Q) for revenue composition and subscription metrics. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceMcKesson has a stake in NVIDIA Canada.
Stephanie David ·11:51
How to verify: Check McKesson's SEC filings or investor presentations for details on its stake in NVIDIA Canada. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceThe average readmission rate for a Medicare patient is 18%, while the average readmission rate for a hospice patient is 6%.
Unidentified speaker (speaker_2) ·31:47
How to verify: Check MedPAC (Medicare Payment Advisory Commission) reports or CMS (Centers for Medicare & Medicaid Services) data on readmission rates by care setting. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
MedPAC studies show that every day of hospice care saves Medicare money and is a net positive for the Medicare trust fund.
Unidentified speaker (speaker_2) ·32:49
How to verify: Search MedPAC reports for 'hospice' and 'Medicare trust fund' impact studies. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Ennoble Care has generated nine figures of EBITDA and has been consistently profitable (eight figures of EBITDA) for over four years.
Stephanie David ·33:58
How to verify: Verify via Ennoble Care's S-1 filing or latest 10-K/10-Q filings if public, or private financial statements if pre-IPO. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceThe IPO revenue bar has shifted from $100M to $200M, and now requires $300M-$500M in revenue with profitability.
Stephanie David ·39:31
How to verify: Review recent healthcare IPO prospectuses and market analysis reports from 2026-2026 to compare revenue levels of successful listings. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceInvestors are no longer willing to fund unprofitable companies with no clear path to profitability.
Stephanie David ·39:58
How to verify: Analyze VC funding rounds and IPO rejections in healthcare tech/services from 2026-2026 for profitability requirements. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Management teams attempting to 'game' their sector classification face rejection from investors with strict mandates.
Unidentified speaker (UNKNOWN) ·45:45
How to verify: Review investor feedback in IPO roadshows or private funding rounds where sector classification was disputed. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Ennoble Care serves 50,000 medically frail seniors across 17 states.
Christina Farr ·28:53
How to verify: Verify via Ennoble Care's S-1 filing or latest 10-K/10-Q filings. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceHospice care is provided in the home in most cases, not in a facility.
Unidentified speaker (speaker_2) ·32:29
How to verify: Check CMS data on hospice care settings or National Hospice and Palliative Care Organization (NHPCO) reports. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Ennoble Care has more EBITDA than primary capital raised, more EBITDA than debt, and more cash than debt.
Unidentified speaker (speaker_2) ·34:18
How to verify: Verify via Ennoble Care's S-1 filing or latest 10-K/10-Q filings. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceThe average senior takes 12-14 medications and sees 7-9 specialists.
Unidentified speaker (speaker_2) ·54:56
How to verify: Check academic studies or industry reports on senior medication usage and specialist visits. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
AthenaHealth started as a women's health care provider before building an EHR system.
Christina Farr ·57:28
How to verify: Review AthenaHealth's corporate history or SEC filings (if public) or press releases detailing their founding and pivot to EHR software. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Verify Option Care Health's acquisition terms and strategic rationale via Cencora and McKesson SEC filings (S-4 or 8-K).
- Check Ennoble Care's patient volume and geographic spread against their stated 50,000 patients across 17 states.
- Review MedPAC reports on hospice care savings to Medicare to validate claims about trust fund impact.
- Assess ICR Healthcare's IPO revenue thresholds against recent public market transactions for healthcare services companies.
- Evaluate AI companies' token usage costs versus reported efficiency gains in their 10-K or earnings reports.
- Compare Ennoble Care's unit economics and EBITDA margins to industry peers in home-based primary care.
- Investigate the XBI index performance drivers to determine if gains are broad-based or concentrated in AI-drug discovery stocks.
Full transcriptexpand
- 0:15
- Unidentified speaker (UNKNOWN): Hi
- 0:15
- Christina Farr: everyone, and welcome back to Rounds where Healthcare meets Wall Street. We are officially back for season two, and I'm Christina Farr, joined by my co-host Stephanie Davis.
- 0:26
- Stephanie David: We're back and better than ever.
- 0:28
- Christina Farr: It's so good to be back, and we've got the most amazing packed first episode. Definitely stick around. A lot has happened in healthcare and AI these past few weeks, and we have two strong guest segments lined up to talk about it.
- 0:42
- Stephanie David: Thank you so much, Chrissy. But before we dive in, a big thank you to our sponsors. This episode is sponsored by ICR Healthcare, who will be joining us later. this episode to talk about what's going on in the healthcare capital markets. And we have the whole season sponsored by Butterfly Network. Thank you to both. Let's get into it. Chrissy, we just actually had some
- 1:02
- Stephanie David: news that came out. You're a big SOS second opinion summit. Tell me how it went.
- 1:07
- Christina Farr: Well, you were there, Stephanie. So I'd love your thoughts as well from the ground. But yeah, it was dedicated to exploring the topics of healthcare. and AI. We had folks there from really across the whole industry, people from pharma, health systems, um, of course, payers, operators, founders. So I would say a couple big themes
- 1:26
- Christina Farr: shone through. And we had a few days to talk about where it's all going in Williamsburg, in New York City. So my my big takeaways, I would say, from from this year, number one, everybody is. full steam ahead on AI and healthcare. And while there were a lot of concerns about safety, um, especially with all the recent news
- 1:46
- Christina Farr: and doomsday talk,
- 1:49
- Christina Farr: um, P Doom, in healthcare, AI is so important. And we really have this unique opportunity to do something real here. And so people are saying all systems go. And then I would say probably my other big takeaway is that there is just a lot of learning happening inside many of these companies. You only hear on the surface of it that
- 2:08
- Christina Farr: everything's going great, AI is streamlining processes and improving efficiencies. And when we really got into it, and the whole summit, by the way, was Chatham House rules, so we kept it confidential, but people confided in the attendees that employees had spent millions of dollars on token maxing without any. clear ROI. And that
- 2:28
- Christina Farr: there were a lot of learnings about how to actually deploy AI within organizations. A couple of folks said, for instance, that they had sorted out with more of a bottoms-up approach, telling employees, like, hey, you got to get trained in AI. You got to start using it in your day-to-day life. But without that bottoms-down motion where leadership really takes a role, it just
- 2:48
- Christina Farr: hasn't been working. It's been falling flat. So we had some really cool insights like that that I think showed that, you know, we're still learning, we're still evolving, and we need this kind of real talk to be able to learn from our peers. What were some of your takeaways, Stephanie?
- 3:02
- Stephanie David: You know, I feel like whenever we talk about AI, we talk about these AI startups, right? Health tech startups are gonna go and disrupt everything in AI. I was kind of surprised and intrigued to discover that a lot of the encounters incumbents had a huge advantage. Like you mentioned with that token maxim comment, how it was incredibly expensive as folks were starting to go in and develop
- 3:22
- Stephanie David: their AI solutions. If you're an existing incumbent with a clean data set or a cleanable data set,
- 3:29
- Unidentified speaker (UNKNOWN): I
- 3:29
- Stephanie David: mean, you're probably in the capburn seat to make AI work for you. And if you're an AI startup and you're not fully proven out yet, uh, I don't know if it's the time to get funding. People really want solutions that are real right now.
- 3:45
- Christina Farr: I would totally agree with that. And sometimes we think of the incumbents as less strategic and less sophisticated than they actually are. And I do think they're in a really good position right now. That said, there are a few physicians that made some very pointed comments on stage about how AI felt forced on them. Um, by their own administrative
- 4:05
- Christina Farr: leadership. And so we still need to continue to have this dialogue about what are the right constructive ways to use AI that actually puts the patients first.
- 4:14
- Unidentified speaker (UNKNOWN): Yes.
- 4:15
- Stephanie David: AI for the sake of AI, I think is going to be a terrible miss. You know, you heard some of the different providers talk about in-house developed AI. That didn't work. We did in-house developed software in Healthcare. That's a crazy idea. But I do think anything that reduces friction, that's gonna be a huge opportunity for AI. Anything that adds more
- 4:34
- Stephanie David: friction, I mean,
- 4:35
- Unidentified speaker (UNKNOWN): we
- 4:36
- Stephanie David: saw how much folks love their EHRs, right?
- 4:39
- Christina Farr: Well, one thing I did that I was I was quite proud of with the summit, just to keep it real, is that we had a patient story to kick off the conference and a patient story to end the conference.
- 4:48
- Unidentified speaker (UNKNOWN): So
- 4:49
- Christina Farr: back to home. Grounding, exactly. Um, so while we're on the topic of AI and healthcare, I wanted to bring up two recent bits of news that I thought were pretty interesting. The first one is that NVIDIA just bought a stake in a number of French tech startups, um, including a company called Doctor Lib. Um, and we we've
- 5:09
- Christina Farr: seen Anthropic partnering with drug makers to test flawed in drug discovery. What do you make? of this?
- 5:15
- Stephanie David: I mean, remember when all the the big tech incumbents were like the acquirers of of the dreams? It's like, oh, maybe Google bias, maybe Microsoft will bias. Now I think it's like maybe OpenAI, maybe Anthropic, maybe NVIDIA. They're uh the new acquirers of hope, if not of choice.
- 5:33
- Christina Farr: And why healthcare of all the segments that they could be focusing on? Why do you think we've seen them? pick up companies like DoctoLib,
- 5:42
- Christina Farr: which is in the space of helping tens of millions of patients book appointments across Europe? So there is distribution and inference demand there in one move. And then we've got anthropic really calling out life sciences as an area of focus, and particularly in trying to find new promises.
- 6:02
- Christina Farr: promising new molecules. So, why those segments of the industry and not something else that maybe is a little bit easier than healthcare?
- 6:11
- Stephanie David: The TAM, Chrissy, we have a giant TAM, right? If you're if you're anthropic and you went through their S1, they mentioned healthcare a bunch of times because that's a huge opportunity if we can create efficiency. I do find it interesting that we're doing a little bit more for our anthropic in biotech space, just because the XBI has had
- 6:31
- Stephanie David: a huge move, that's a biotech index year to date. I think it's up over 25%. And a lot of it is on the thesis that AI drug discovery is going to change that business model. I think Anthropic saw that and said, no, no, no. We own that business model. We are the AI players. And we're going to do little tuckens tuck-ins to make sure that this is a solution we can
- 6:51
- Stephanie David: get.
- 6:52
- Christina Farr: And where do you think this um in when we look at anthropic and life sciences, do you think we're talking about more molecule design? Are we talking about regulatory drafting, or are we moving into clinical trial operations and speeding up the time it takes to get a drug to market? Which of those areas do you think anthropic and some of
- 7:12
- Christina Farr: these frontier model companies can have the biggest impact?
- 7:15
- Stephanie David: I mean, there's so much inefficiency in that space. I think there's a huge opportunity for each of the areas you mentioned. Drug discovery and design would be huge just because right now it's very much trial and error. And I think the the ability to trial and iterate is much faster for all these AI models.
- 7:31
- Christina Farr: Yeah, I would agree. I mean, it takes what a billion dollars essentially these days. So
- 7:36
- Unidentified speaker (UNKNOWN): you know,
- 7:37
- Christina Farr: it it makes sense. I think it's why. worth pointing out as well that, you know, all these results are still very early. It's very much still in the lab stage and company reported. So this is one to watch versus something that, you know, is gonna cure cancer in the next six months.
- 7:53
- Unidentified speaker (UNKNOWN): Yeah,
- 7:53
- Stephanie David: I mean, well, here's hoping. Now here's another AI take in the news. Uh I heard a lot of buzz in the like fintech space and the tech space about these agentic fears. disrupting business models. The agentic bank run was a big one. The Polk's use an example. That consumers are having um inefficiency in their their interest rates for
- 8:13
- Stephanie David: their banks just because you can't optimize for rates. There's only so many hours in a day. And an agent can solve for that, but maybe change the the dollars available at different banks. How do you think that affects healthcare?
- 8:25
- Christina Farr: Yeah. I mean, if if um healthcare, if we think about healthcare, you know, we think about the the idea of using agents. And um we're talking about this now ad nauseum. I think healthcare today runs off of inefficiencies. And you
- 8:40
- Unidentified speaker (UNKNOWN): mentioned
- 8:41
- Christina Farr: friction, it runs off of friction.
- 8:43
- Stephanie David: That's our market.
- 8:44
- Unidentified speaker (UNKNOWN): That is essentially our market.
- 8:45
- Stephanie David: Efficiencies and friction.
- 8:46
- Unidentified speaker (UNKNOWN): And think about
- 8:47
- Christina Farr: how many companies have been successful off the back of that. I think the the whole point of agents is that there is going to be far less inefficiency and friction. So what does that do to healthcare business models? That's the big question.
- 9:02
- Stephanie David: It makes me a little worried. I mean, the initial kind of tranche, I would say, is the inefficiency and being able to get out of your subscription model, right? I think hymns, HIMS row, those are things where I've heard. a lot of consumers say, we cannot get out of getting these hair pills for the rest of my life. So I guess I'll just keep paying
- 9:21
- Stephanie David: for them. Um, but I look at a lot of the D2C business models, right? Like BetterHelp has pivoted away towards being more of an insurance cover product. Thank God, because that's something where you also saw some consumer friction issues. Life MD, I think they had something like um 84% of their revenues were coming from recurrent. recurring subscriptions. I also wonder if it
- 9:41
- Stephanie David: changes the business models that can be created. Think of Good Rx. Good RX exists because comparing prices for how to pick up your prescriptions across different pharmacies is a tedious task. You're not doing that.
- 9:55
- Unidentified speaker (UNKNOWN): But
- 9:55
- Stephanie David: Good Rx could, but maybe agents could in the future.
- 9:59
- Unidentified speaker (UNKNOWN): Yeah,
- 10:00
- Christina Farr: I think that's that's really to me, that's like the obvious is. any business that runs off of you get a subscription, you forget about it, you know, it saves you 15 minutes of of time and having to look things up across multiple websites. Any of those businesses to me are immediately really troubled because of
- 10:19
- Christina Farr: agents. I think the bigger question is, what about all these middlemen? You know, where, you know, whether it's a PBM, whether it's a drug distributor, what is the long term for businesses like that that literally exist to be a go-between between two much larger industries?
- 10:36
- Stephanie David: I mean, drug distribution. I I used to cover that sector, and I always have people say, hey, what do they do? At their core, they distribute drugs. They ship them out. So that's not going away. But think about the friction business models. Think about care navigation.
- 10:53
- Stephanie David: Care navigation is you don't really know how to navigate care. You need an expert to ask, and you're gonna call up a human to do that. So the margins weren't great. Could an agent do that? Couldn't they shop around for you?
- 11:04
- Christina Farr: It's absolutely plausible. Speaking of distributors, I know with uh with your background, Stephanie, um, when you're an analyst, you will love this one. Option care health agreement. agrees to f a $5.8 billion acquisition by C DR and McKesson at $32.05
- 11:23
- Christina Farr: per share. So this is clearly about getting into the growing home infusion market. Stephanie, thoughts?
- 11:31
- Stephanie David: I mean, I think you've seen the distributors get interested in all these venues for specialty meds, right? You've seen a big roll roll-up up of a college. oncology practices. Um, there's a huge acquisition of Florida cancer specialists. So I think you're seeing more and more of that. And McKesson realized that infusion is a huge area of specialty care. Huge. And so you're probably
- 11:51
- Stephanie David: going to see them have more Me To's, kind of more followers of this. I wouldn't be shocked if the Sincoras and the Cardinals of the world also were for looking at other infusion players. And McKesson just had a headset. head start because they had NVIDIA in Canada. So they have uh a lot of opportunities for that. Now, what surprised me, that was a healthy multiple,
- 12:11
- Stephanie David: right, Chrissy?
- 12:12
- Christina Farr: Absolutely. But I think you gotta pay up for businesses like this, especially if you look overall at the expected growth for the home infusion market. It's going up and up and up every single year. And it it's part of this broader trend, Stephanie, that increasingly we're gonna see going to care performed outside of both hospital and provider settings. Not
- 12:32
- Christina Farr: to mention, we've got a really robust pipeline of new drugs coming to market that involve home infusions. And we're seeing more diagnoses of these complex conditions that require these types of drugs that get used at home. So I think lots of contributing factors, not to mention the socioeconomic trends that you and
- 12:52
- Christina Farr: I have talked about so much, where our population is getting older and more medically complex.
- 12:58
- Stephanie David: And you know, maybe that's worth the 37% premium. I think it's a pretty healthy thing. I think about AI, you know, we talk about a lot in this program. We all say, Oh, what's getting disrupted? What's getting disrupted? It's just as important to call out what's not getting disrupted, right? The drug distribution. I will tell take the drugs from point A to point B. Infusion
- 13:18
- Stephanie David: care, I will go to your home, I will make sure you're able to have the drugs inserted intravenously. Like all of those things are are impossible to disrupt.
- 13:28
- Christina Farr: I think aspects of it will become more efficient, just communicating where you know certain pieces are in the process of moving them from A to B. But I absolutely agree with you that these are really, you know, it's it's human beings that need
- 13:44
- Unidentified speaker (UNKNOWN): to be
- 13:44
- Christina Farr: involved in this kind of work. And I
- 13:45
- Unidentified speaker (UNKNOWN): think it
- 13:46
- Christina Farr: presents a really big opportunity for the healthcare industry. Um, as we take away some of the jobs that are more on the administrative side of healthcare, having more people who can help out with these aging seniors at home or people who are medically complex and need help. To me, that's that's an absolutely growing area.
- 14:06
- Stephanie David: From a friction industry to a logistics industry. I like it.
- 14:09
- Unidentified speaker (UNKNOWN): So
- 14:09
- Christina Farr: that's all the news for this episode. Let's bring out our first guests.
- 14:17
- Stephanie David: One quick thing before we start: the most powerful thing you can do, and it costs you nothing, is to subscribe to this channel and follow if you're listening on Spotify or Apple Podcast. Podcasts. It means everything to me and to Chrissy and the small team that puts this together every week.
- 14:31
- Christina Farr: We'd also love to hear from you about what you liked about the show, what you didn't like about the show, what do you think of the guests, and who should we have on next? Drop us a line in the comment section below.
- 14:46
- Christina Farr: Joining us now Kush Doss and Molly Viscotti from EnoboCare. Ennoble Care. Welcome.
- 14:51
- Unidentified speaker (speaker_2): Thank you.
- 14:52
- Christina Farr: Well, I'm super excited to talk about in Ennoble because you're doing something that we haven't really talked about much on the program. Taking care of primary palliative and hospice care for medically frail seniors. And that is such an important thing. This is the kind of thing that Stephanie and I were just talking about that this is this is an
- 15:12
- Christina Farr: area that is basically immune to AI.
- 15:16
- Christina Farr: Do you do you want a robot taking care of this population, or
- 15:19
- Unidentified speaker (UNKNOWN): do you need a
- 15:20
- Christina Farr: sympathetic and um well-trained human being?
- 15:24
- Unidentified speaker (speaker_2): Well, I think we um take a lot of pride in that our 1700 clinicians are not going to lose their jobs anytime soon with any amount of robots because the people need a human touch. I mean, that's why it we have all the things that we think about with in-home care. with small patient panels. Like you need that one-on-one interaction, that nursing mindset, which
- 15:44
- Unidentified speaker (speaker_2): you know, maybe 30, 40 years from now there are in fact robots. But for now, there are not. So we like that.
- 15:49
- Unidentified speaker (speaker_3): Yeah. And we're all about using technology to help our clinicians take care of the patients, but it's definitely not replacing the clinicians for sure.
- 15:57
- Christina Farr: So can we talk a little bit about what you're doing and how you ended up build building this business? What gave you the idea for this business? I think maybe tell us like both about the mission of the company, the motto of the company, which I love. And then for both of you, like a little bit about your own stories.
- 16:15
- Unidentified speaker (speaker_2): Yeah. So my background, I actually started out driving ambulances. So I drove ambulances for almost 15 years, uh, worked full-time full time in college and part-time in law school, uh, taking care of the same patients we take care of. now. So a bunch of people that used a 911 as their primary source of healthcare, which sounds insane, right? Who wants to go to a hospital? Basically no one.
- 16:35
- Unidentified speaker (speaker_2): But when you have no other choice, when there's no other option available, that's what you do. You call 911, you go to the emergency room, spend four hours in the waiting room of the emergency room, then spend a week in the hospital for absolutely no reason except that you didn't get any care anywhere else. And so that background, uh for me started there, became a healthcare lawyer, became a consultant,
- 16:55
- Unidentified speaker (speaker_2): and decided to start this. And it, you know, Molly saw the whole thing from the other side actually as a nurse. So
- 16:59
- Unidentified speaker (speaker_3): Yeah, so I started my career as nurse uh here in New York. I was a labor and delivery and ER nurse for a few years. Um, got really interested, obviously, being a direct care clinician, you can have a lot of impact on individual patients and their families in any a given shift, but got really interested in sort of how our healthcare system. is designed. Went back and did a PhD,
- 17:18
- Unidentified speaker (speaker_3): did health outcomes and workforce management, and then went into consulting where Chris and I met.
- 17:23
- Christina Farr: Do either of you have a specific patient that was your reason for starting the company?
- 17:29
- Unidentified speaker (speaker_2): Oh, interesting. Well, I have a really memorable patient. Um I don't think she was necessarily the reason for me to start a company, but I think uh I saw a lot of the her pain, which stuck with me over 10 plus years. She was uh uh elderly widow, uh, I think she I don't know her exact age, but
- 17:48
- Unidentified speaker (speaker_2): must have been early 80s or something like that, uh, that resided in a wheelchair. So she had Parkinson's, couldn't uh walk herself, uh, and she didn't have any family that lived with her. And so her daughter did come and visit quite. a bit, and her daughter was, you know, absolutely essential to her life. But uh her daughter didn't come enough where she could
- 18:08
- Unidentified speaker (speaker_2): check on whether she'd got her medication refills, whether her hospital bed was in decent shape, whether someone would come for her mobile labs. And so when she got sicker and sicker and sicker, which happened in like a cyclical Whole way every couple months, of she would call 901 and
- 18:24
- Unidentified speaker (UNKNOWN): uh
- 18:24
- Unidentified speaker (speaker_2): I would show up or one of my colleagues would show up. I used to work a lot, so it ended up being me showing
- 18:30
- Unidentified speaker (UNKNOWN): up
- 18:30
- Unidentified speaker (speaker_2): probably too many times, but would take her to the ER and she was really pleasant. Like she was a really nice human being and like had a great uh like outlook on life, remarkably positive outlook on life, and just had no other choice. Um, so I think about her a lot. She had, you know, ten different things wrong with her. We used to take her Ziploc Lock bag with her pills, which must have been, I don't know, like fifteen 15 different little pill
- 18:50
- Unidentified speaker (speaker_2): bottles in there. that we'd carry to the ER to make sure they were aware of all the stuff going on. And uh she actually had, which was really fun, she had a little binder of her medical records. And so we would grab the binder every time because we knew where the binder was, and we'd also bring in because you know, if one ER was diverted, they wouldn't have our record, so we'd bring it to a different one. So it was that's the crazy
- 19:10
- Unidentified speaker (speaker_2): thing in Jersey, which is now one of our biggest markets, actually. But um, that's the most memorable. one I can think of the top. I
- 19:15
- Unidentified speaker (UNKNOWN): don't
- 19:15
- Unidentified speaker (speaker_2): know if you have one off the top of your
- 19:17
- Unidentified speaker (speaker_3): well-informed patient that comes up with a binder too
- 19:21
- Unidentified speaker (UNKNOWN): in the
- 19:21
- Stephanie David: original personal health record,
- 19:22
- Unidentified speaker (UNKNOWN): right?
- 19:23
- Unidentified speaker (UNKNOWN): Exactly.
- 19:24
- Unidentified speaker (speaker_3): Um I think for me as a group of patients specifically with congestive heart failure that we kept seeing over and over in the ER. And for a lot of these patients as an ER nurse, you're doing these discharge instructions and you know, pages and pages that you're sending them home to um obviously weigh themselves, but also to monitor their fluid on a daily basis and like trying to teach patients about their
- 19:44
- Unidentified speaker (speaker_3): nutrition and hydration and how that impacts. And you just get this sense after seeing them a few times that like whatever I'm trying to do with this education is not sticking. And I'm gonna keep seeing them again and again. And so to me the idea of being able to meet people where they are, where their pill bottles and their binders and you know and really take care of them and show them what to do there. Uh so appealing.
- 20:03
- Stephanie David: That must have been so frustrating to see this and say, I wish I could help. I know I can't.
- 20:08
- Unidentified speaker (UNKNOWN): I know I
- 20:08
- Stephanie David: can't.
- 20:09
- Unidentified speaker (speaker_3): Exactly.
- 20:10
- Stephanie David: Now
- 20:11
- Unidentified speaker (UNKNOWN): I
- 20:11
- Stephanie David: find it interesting that when look you guys up, I hear a lot about value-based care. And I'm a former public markets person and I think of pub value-based care as uh a kind of a dirty word.
- 20:21
- Unidentified speaker (speaker_2): Oh, it's such a dirty word.
- 20:22
- Unidentified speaker (UNKNOWN): I have a dirty
- 20:23
- Unidentified speaker (speaker_2): word. Yeah.
- 20:23
- Unidentified speaker (UNKNOWN): You know, folks don't love it.
- 20:24
- Unidentified speaker (speaker_2): Yes.
- 20:25
- Stephanie David: So so tell me. was there something that these public players did that was wrong in value-based care? Or is this something where you're gonna convince me that maybe I'll introduce it back in my lexicon?
- 20:36
- Unidentified speaker (speaker_2): Yeah. Well, where do I start? Um I
- 20:40
- Unidentified speaker (UNKNOWN): I
- 20:40
- Unidentified speaker (speaker_2): let me just say first, I think value-based care means so many things to so many people, but I think mostly what it means is that you're not a real business, that you're not self-sustainable. Right? And I think
- 20:50
- Unidentified speaker (UNKNOWN): you heard it here.
- 20:51
- Stephanie David: for a
- 20:51
- Unidentified speaker (UNKNOWN): yeah,
- 20:51
- Unidentified speaker (speaker_2): and it drives me, it drives me insane because I think that's mostly what everyone got wrong for the last uh maybe five to eight years. There was an era of value-based care before it was called value-based care when it was called HMOs, which got a lot of things wrong on the patient experience, but financially actually got a lot of things right. There's parts of the large players, like the large cap
- 21:11
- Unidentified speaker (speaker_2): United to the world, that are actually doing a lot of things really intelligently on combined. combining the people who take on risk for costs of care and the people who are delivering the cost of care. Now they're doing
- 21:22
- Unidentified speaker (UNKNOWN): it
- 21:22
- Unidentified speaker (speaker_2): by actually, you know, delivering good care and also making money from that care and then reinvesting that money into more care. The people in the era of value based care that you're talking about, it was vaporware. I mean, what they were basically doing was raising a ton of cash, taking that cash and putting it on LinkedIn. which a bunch, a bunch of nice like press releases, then taking
- 21:42
- Unidentified speaker (speaker_2): all that cash and essentially lighting it on fire by going to these very CapEx heavy models where they're trying to build these clinics where if you build them, people will come when realizing that customer acquisition in healthcare is impossibly hard. You have to
- 21:57
- Unidentified speaker (UNKNOWN): expensive Thoughtful
- 21:57
- Unidentified speaker (speaker_2): and very expensive. you know.
- 21:58
- Stephanie David: Incredibly expensive.
- 21:59
- Unidentified speaker (speaker_2): Incredibly expensive. So, you know, you got these old players that are spending 50. fifteen hundred dollars acquiring a patient and then losing five thousand dollars on that patient in their first year and hoping that in the third year they're gonna finally make ten thousand dollars to make up for the first two years before they even make their first cent of actual returns. That's
- 22:15
- Unidentified speaker (UNKNOWN): not a
- 22:16
- Unidentified speaker (speaker_2): business model.
- 22:18
- Unidentified speaker (speaker_2): 2020
- 22:18
- Unidentified speaker (UNKNOWN): business model, yeah.
- 22:19
- Unidentified speaker (speaker_2): And you know, sometimes I say we really miss missed the heyday of the 2020s and 2021s of like starting a business five years before then, so you could sell at the right time. But for you shouldn't run a business that way, right? The business should should not be run just to get out when the stuff is hot. You should actually be running it so that you don't need to get out. And that's what we really believe. And and value-based care,
- 22:39
- Unidentified speaker (speaker_2): take that word out for a second. The question is, are you delivering real care? And is the care good enough that you can take on financial risk for that care? That's what it should
- 22:47
- Unidentified speaker (UNKNOWN): be.
- 22:47
- Christina Farr: So I want to talk a little bit about the scale that you've been able to achieve, just to level set folks tuning in on how big this business is. So we're talking about 50,000 patients across 16 states.
- 22:59
- Christina Farr: And you're adding more states, it sounds like, in the next year. But it's a little different than what we see in the pure virtual Morphine for service This world where everybody has
- 23:10
- Unidentified speaker (UNKNOWN): to go
- 23:10
- Christina Farr: all 50 state right away, usually because of contracts with employers. or other groups that expect all 50 state. You guys went a little bit more slowly and you've been tapping into various contracts along the way, which I think it'd be good to to discuss. Tell us a little bit about the rollout and how you got to that
- 23:30
- Christina Farr: 50,000 patient number. And did you how did you resist the pressure to just go, you know, to all 50 states at once?
- 23:38
- Unidentified speaker (speaker_2): Well, I think I still feel pressure to go to all 50 states,
- 23:42
- Unidentified speaker (UNKNOWN): but
- 23:42
- Unidentified speaker (speaker_2): definitely not at once, right? I think that's part of the, you know, you're right, it's 50,000 patients now. We're actually in 17 states as of last week,
- 23:49
- Unidentified speaker (UNKNOWN): which is exceeding. Thank
- 23:50
- Unidentified speaker (speaker_2): you. I think we'll be collect 20 by the end of the year. Um when we think about our growth, it it's you know, two different ways, right? I think the first is when you deliver great care, you have a bunch of people noticing, and the people that are giving us the patients, they say, Hey, we have patients across the state line that you should also get, right? You should also serve these people. They need your help. And so we've gotten a lot of
- 24:10
- Unidentified speaker (speaker_2): adjacent growth. So you'll see, you know, in our expansion, we've kind of we we're both from Jersey. We started in Jersey basically and moved westward and southward over time. The other way that we, you know, have been pretty intentional with our growth is we do find a lot of great practices that are in the market for 10 years, great set of clinicians, great set of
- 24:30
- Unidentified speaker (speaker_2): patients, but they don't have the infrastructure to be self-sustainable. And they need to join a bigger platform. And so we've done 17 Tukken acquisitions now over the last five years as well. So our growth comes, you know, we have a very proud to say a 75% five-year Kager, which not many people can say while being profitable for all five of those years, but about half of that growth is organic.
- 24:50
- Unidentified speaker (speaker_2): about 40% is organic. We've had 40% growth for the last five years, and last year to this year, and this year and next year we will too. And on top of that, we have a bunch of these talking acquisitions that are just great fits. So it's a mix of those things. But isn't anything else to
- 25:03
- Unidentified speaker (UNKNOWN): do? Yeah, and I
- 25:04
- Unidentified speaker (speaker_3): would say with our patients, uh, we aim to have a very longitudinal high-touch relationship. So it's less like lists of patients that we're going out and pursuing, and really our patients coming to us, and in that way they're very sticky. And sort of back to the value based question too, like we are first and foremost providing the care to the patients. And we are the ones that they know are
- 25:24
- Unidentified speaker (speaker_3): providing the care. Like sometimes with some of the value based care companies, especially in the past, like I don't know that a patient would even know who they were or how they were involved in their in their care. That's more about the risk taking than than the service we're providing.
- 25:36
- Stephanie David: Now not not to hate on this, you know
- 25:38
- Unidentified speaker (UNKNOWN): Mah
- 25:39
- Stephanie David: Kush, but you're talking about margins and we've always been profitable. I don't view care delivery, much less PCP care delivery as like the most margin rich area
- 25:49
- Unidentified speaker (UNKNOWN): of
- 25:49
- Stephanie David: the world.
- 25:50
- Unidentified speaker (speaker_2): Yeah.
- 25:50
- Stephanie David: What what are you doing?
- 25:52
- Unidentified speaker (speaker_2): Well, it's not the mar most margin rich area of the world. So I agree with you first and foremost, but I uh we've made it unit economics economic sustainable, right? So our, you know, our as a physician practice go goes, our gross margins are strong, our even margins are enough that we can self-fund our growth with working capital. And I think that's like been our standard of what we consider to be
- 26:12
- Unidentified speaker (speaker_2): great profitability is every dollar you make with cash flow, free cash flow, can you reinvest that to create a forty percent growth rate? That's I believe a good rule of thumb for self-sustainable healthcare services business. The way we do it is I think like some degree of insane efficiency. I think we should talk a little about that and our EMR that we have.
- 26:31
- Unidentified speaker (speaker_3): Yeah. And so I think one of the pieces is we of course have to manage the productivity for the providers. And it is of course very different. And uh from a PCP perspective, like you get reimbursed the same for an EM visit as you would in the clinic. In a clinic you can do, you know, 20 visits, a nurse practitioner can do 20 visits during the day, our providers who are driving around in the field can do maybe
- 26:51
- Unidentified speaker (speaker_3): eight. So it's also figuring out how do we our patients are very sick and very needy. So what are the services they need? And honestly, primary care is always going to be the cheapest of healthcare services. So even though we're providing very frequent high touch every four weeks in the patient's home, multiple touch points in between, it still does save the system a lot of money.
- 27:11
- Christina Farr: Um, can you share a little bit about the motto? I love, I love the, the company's kind of guiding focus. And I think it's the re I think the reason I love it is because it's so different than so many of the messages that we're hearing right now, um, especially in the AI era.
- 27:27
- Unidentified speaker (speaker_2): Yeah. I um so we actually just did our big values launch, which we're really proud of internally with the leadership of the organization, which is now, you know, a 100 hundred of the roughly 2000 employees we have. And those folks, I think, have been hearing this one phrase, which is to care is an honor now for many years. That was one value that we didn't have to remind them of.
- 27:47
- Unidentified speaker (speaker_2): It's been front and center for a long time. I think what it means to us is uh we are actually privileged to have the patient trust us to provide the care versus the patient being somehow the, you know. in the position of privilege or luck or
- 28:06
- Unidentified speaker (speaker_2): happenstance. Yeah. It's a the patient is choosing us. We are so lucky to have them choose us. And we're gonna take that with all of the responsibility that comes with that, where every encounter actually matters uh as if it's the most important encounter in our lives, just like it is in fact the most important encounter or one of the most important encounters in the patient's lives, right? Because they're in a state of crisis. They're uh
- 28:26
- Unidentified speaker (speaker_2): often unable to do anything without the kind of support that we're providing. And so it should be as important to us as it is to them, if not more, which we hope for many of our clinicians it is in fact more.
- 28:37
- Unidentified speaker (speaker_3): Yeah. And I think one of the things that happens in healthcare to healthcare companies, especially as they get bigger, is it becomes like a little bit more like sterile. Like it becomes
- 28:44
- Unidentified speaker (UNKNOWN): a little
- 28:44
- Unidentified speaker (speaker_3): farther they're removed from like why individual like most of our employees are clinicians, they're nurses, you know nurses aid, medical assistants.
- 28:52
- Unidentified speaker (UNKNOWN): And
- 28:53
- Christina Farr: they're employees.
- 28:53
- Unidentified speaker (UNKNOWN): I think that's
- 28:54
- Christina Farr: worth stressing.
- 28:55
- Unidentified speaker (speaker_3): Yes.
- 28:55
- Unidentified speaker (UNKNOWN): They're not
- 28:55
- Christina Farr: contractors.
- 28:56
- Unidentified speaker (speaker_3): No, they're all our employees. And like they're not, you know, like the reason that they chose to work at a noble is because we provide amazing care, you know, and to Kush's point, we are going into patients' homes, which is, I think, probably like the most intimate of all care settings. And really having that every time we go in it is an honor to be able to be
- 29:16
- Unidentified speaker (speaker_3): there. Um, for our house calls patients, primary care during the last few years of life, and then for our hospice patients where in their last few months of life being part of their, you know, family and their journey is so important. And so we um, you know, use it a a lot. I think that to care is an honor as as our motto, but it it really rings show. true.
- 29:36
- Stephanie David: And you you mentioned your frequent flyer patient, where you got so integrated you knew where her binder was. How often are your clinicians seeing their patients?
- 29:46
- Unidentified speaker (speaker_3): Yeah, so on the primary care side, we're in the home uh every four weeks for a stand-in patient. After a hospitalization, it'll be every week or two, or if they have a complex wound. So we are physically in their home, Um, you know, at least once a month. In between, we have a group of care coordinators or medical assistants sit in the office. and some of our patients call us literally every day. You know, like we are their
- 30:06
- Unidentified speaker (speaker_3): first call, we are their um trusted resource. Um but yeah, I I would guess that most of our providers know where all the binders
- 30:13
- Unidentified speaker (UNKNOWN): are, all the pillboxes.
- 30:15
- Unidentified speaker (UNKNOWN): All the binders are the binders.
- 30:18
- Unidentified speaker (speaker_3): And the magnets, the fridge magnet is a big one
- 30:20
- Unidentified speaker (UNKNOWN): with
- 30:20
- Unidentified speaker (speaker_3): uh older other people as well.
- 30:22
- Unidentified speaker (UNKNOWN): I
- 30:22
- Christina Farr: wanted to share um one little quick story about an episode we did with the former Aetna CEO Mark Bertolini that I thought might resonate with you. And this is on our our other podcast, Lifers. So you should check it out and we'll we'll give you a link in the comments. Um but Mark he had a ver a son who had cancer and um was very, very sick.
- 30:42
- Christina Farr: And um
- 30:43
- Unidentified speaker (UNKNOWN): at
- 30:43
- Christina Farr: a certain point they started to Let's talk about hospice. But uh they still held out some hope because he was a young guy and there it's it seemed like there might be some treatments um available to him. And so um Mark realized that his own insurance company, as well as other insurance companies, had policies in place saying that you had to basically sign a letter uh
- 31:03
- Christina Farr: certifying that you knew you were going to die to go into hospice, and that was keeping a lot of people out of hospice, remaining in um hospital settings where they didn't necessarily want to be from a quality of life. perspective. So he mentioned changing that policy at Aetna for his own son. And then, you know, one two surprising things happened.
- 31:23
- Christina Farr: One of them was that his son ended up surviving and making a miraculous recovery. And the second surprising thing was that it was a very good business move for Aetna because is a they saw a huge spike the following years in people going into hospice. And I love that story because it shows that having that proximity to the patient and the human side of
- 31:43
- Christina Farr: healthcare can actually translate to to good business.
- 31:47
- Unidentified speaker (speaker_2): Absolutely. I um
- 31:49
- Unidentified speaker (UNKNOWN): you
- 31:49
- Unidentified speaker (speaker_2): know just some numbers I think to start with is uh the average readmissions rate for a Medicare patient is eighteen percent. The average readmissions rate for a hospice patient is six percent. So that is a massive amount of impact. by the hospice benefit. So we have hospice in seven out of our 17 states. That story is a great example of what I'll
- 32:09
- Unidentified speaker (speaker_2): call like a patient that doesn't expect it, doesn't expect end of life, and doesn't isn't ready yet for end of life, still should get the benefit of hospice because of the care being delivered in the home. And I think, you know, many misconceptions exist about hospice. I think number one, if people imagine that you're in a facility somewhere, in most
- 32:29
- Unidentified speaker (speaker_2): cases, that's not true. In most cases, hospice is provided in the home, in the place that you're comfortable. You're in your own bed with your own kitchen and your own bathroom and your own family. And that can make all the difference because now you're getting someone showing up to your house every day instead of showing up to your house really never, right? That's a one kind of massive difference. By doing that,
- 32:49
- Unidentified speaker (speaker_2): you are saving the system money. MedPAC, which is the Medicare Patient Advisory Commission, has now, um sorry, payment advisory commission, has now done multiple studies to say every day of hospice, every six month period actually does save Medicare money. It is a net positive for the trust fund.
- 33:06
- Unidentified speaker (UNKNOWN): If
- 33:07
- Unidentified speaker (speaker_2): it's a net positive for the trust fund and it's a net positive for Aetna, then I think many other folks should actually follow that exact trend if uh more hospices hospice almost is always better. Obviously you have to be very cognizant about you know fraud and abuse issues, you have to be very cognizant about making sure the care is delivered in the right way at the right time and high quality. But when it's done right, it's absolutely beneficial. And I'm glad I mean
- 33:27
- Unidentified speaker (speaker_2): that's a terrible thing to go through for anyone, especially with this, you know, what the child that is so young. But I think the one of the things that comes out of people who directly experience the hospice benefit is they get rid of all those kind of uh misconceptions that exist about hospice, which is wonderful.
- 33:44
- Stephanie David: Now I hear about you guys a lot because you're out there meeting investors. We've talked about how value-based care is tough in the public markets. We've talked about how, you know, Medicare, Medicaid, that's also had some headwinds this year. Why go public? Why
- 33:57
- Unidentified speaker (UNKNOWN): I
- 33:58
- Stephanie David: do it? Like
- 33:58
- Unidentified speaker (speaker_2): why did I I I you know don't know sometimes I'm just kidding, I do know. Um, but no. we just you have to step back on our business now. So we're now you know nine figures of EBITDA. Um we've been consistently eight figures of EBITDA for over four years now. So it's been a you know history of profitability that we have uh we've generated enough free cash flow, in fact, that we have today you know
- 34:18
- Unidentified speaker (speaker_2): more EBITDA than primary capital we've that raised. We have more EBITDA today than debt we have, we have more cash today than debt we have. Those are things that allow our balance sheet to be, you know, pretty uh durable, but also it allows us to maintain a decent amount of control over the business. So, you know, I'm the large shareholder. We have a bunch of minority shareholders besides us that are great minorities,
- 34:38
- Unidentified speaker (speaker_2): that have come in over time been tremendously supportive. I actually think the public markets do a pretty nice job for healthy businesses with healthy balance sheets to have a really good long horizon view. Like if we are talking about building a business that serves millions of Americans that are stuck at home that need the care we're talking about, it's not a bad idea to have good
- 34:58
- Unidentified speaker (speaker_2): liquidity among the cap table. It's not a bad idea to have constant access to capital as new opportunities come up. And it's a I think a pretty decent amount of opportunity that comes just from the visibility of the public markets as well. And no one knows home based primary care exists.
- 35:13
- Unidentified speaker (UNKNOWN): No
- 35:13
- Unidentified speaker (speaker_2): one knows. Is
- 35:14
- Unidentified speaker (UNKNOWN): this This fair? fair.
- 35:15
- Unidentified speaker (speaker_2): And they should know, right? And that's one of those crazy things where like if someone just uh told, you know, the seven million Americans that could get this, or probably more importantly, their family members that they could get this, maybe someone would pick up the phone and we'd be able to help some more people.
- 35:29
- Christina Farr: Most people want to be in the home, bottom
- 35:31
- Unidentified speaker (UNKNOWN): line.
- 35:32
- Christina Farr: They do not want to be at the hospital.
- 35:33
- Unidentified speaker (speaker_2): Yeah.
- 35:34
- Christina Farr: And that's where the majority of Americans are ending up. Thank you so much for joining us.
- 35:39
- Unidentified speaker (UNKNOWN): Of
- 35:39
- Unidentified speaker (speaker_2): course,
- 35:39
- Unidentified speaker (UNKNOWN): thanks for having
- 35:39
- Unidentified speaker (speaker_2): us. Really appreciate it.
- 35:41
- Stephanie David: Well, thank you for joining us. And next up, we have the ICR Healthcare team to tell us more about what's going on in the public markets.
- 35:52
- Unidentified speaker (UNKNOWN): All right,
- 35:52
- Stephanie David: moving on to our last guest. We got Jordan Constant and Samir Kamad Cohn, both from ICR Healthcare, our sponsor for the episode. Guys, thank you much.
- 36:01
- Unidentified speaker (UNKNOWN): Thank you. So we
- 36:02
- Christina Farr: should talk a little bit about what ICR does. You guys advise healthcare companies. So many of the existing guests we've already had on the show have been advised by you about going public. And you have a front row seat to what's happening. Um, so can you both give us a little bit of the lay of the land? Because
- 36:22
- Christina Farr: what Stephanie and I have been hearing, especially with season one, is do not go. public. Is that is that the advice that that you guys are giving out or does it really depend?
- 36:32
- Unidentified speaker (UNKNOWN): I
- 36:32
- Unidentified speaker (speaker_3): think it really depends. It's it's not an easy path, uh, but for some companies it's the right path. Um and so what we want to do at ICR is make sure that they do
- 36:43
- Stephanie David: it well, um, thoughtfully and avoid the missteps that other companies in their uh, you know, similar paths have have had happen.
- 36:54
- Unidentified speaker (UNKNOWN): Yeah,
- 36:55
- Stephanie David: I think I would say the
- 36:57
- Stephanie David: one thing that we always tell our clients is excuse me, the business will tell you when it's ready. Um there's we've seen and and you know, and we'll tell you a little bit about ICR, but we
- 37:11
- Unidentified speaker (UNKNOWN): uh
- 37:11
- Stephanie David: work across
- 37:13
- Unidentified speaker (UNKNOWN): all
- 37:13
- Stephanie David: aspects of healthcare. And you know, particularly within my business, which is in capital markets, I do everything that is ex biotech and Jordan, you know, leads our our healthcare services and technology practice. We have seen this particularly in the med tech space where over the last 12 months or so there has
- 37:33
- Stephanie David: been this, or maybe 15 months, where there has been this
- 37:37
- Unidentified speaker (speaker_2): um maybe V. view on the part of certain board members that they want to go public just because they're scared of the the market, you know, the window closing. And that has led to a, you know, a plethora of subscale companies that have tried to go public or have gone public. And that has
- 37:57
- Unidentified speaker (speaker_2): put a ball pall on um investors' mindsets.
- 38:01
- Unidentified speaker (UNKNOWN): With a very with
- 38:02
- Unidentified speaker (speaker_2): a very clear view. now where the view on scale within MedTech has changed dramatically. I would say to some extent that has happened in healthcare tech as well, right? Where we know who we are talking about. There were certain companies that wanted to hit a window, but were just not ready. And in their case, the The
- 38:22
- Unidentified speaker (speaker_2): the investors clearly told them, like, this is subscale, like we are not going. to invest in this if you come out at these revenue levels. So long-winded way to answer your question. I think
- 38:35
- Unidentified speaker (speaker_2): there is a market. We hope it opens up next year. It'll probably be more services-oriented
- 38:43
- Unidentified speaker (speaker_2): at the beginning, because services has definitely done well. But I think healthcare tech, um, you'll probably see bigger. companies with much more kind of developed platforms, really good go-to-market strategies, and clear path to profitability. Sorry, long answer to
- 39:02
- Unidentified speaker (UNKNOWN): a
- 39:02
- Unidentified speaker (speaker_2): question.
- 39:02
- Christina Farr: No, I think I think it's spot on. And I I would love to hear from both of you what you think that scale needs to be. Because I remember like 15 years ago when I was starting out as a journalist, all these companies had about you know, 100 million in revenue. And if you got there, you could talk about going public. It's clearly shifted. You
- 39:20
- Unidentified speaker (UNKNOWN): need a
- 39:20
- Christina Farr: lot more revenue than that. And then, you know, we should talk about what kind of revenue, because not all revenue is created equal. So um maybe we'll start with you, Jordan. Where do you how do you think the bar has shifted?
- 39:31
- Stephanie David: Yeah, I think I I remember it when it was a hundred million and then it got, you know, in the last round of IPOs, it was more like needed to be approaching two hundred. 200 million. I think now you need to be like three to five.
- 39:43
- Unidentified speaker (speaker_2): Yeah.
- 39:43
- Stephanie David: Um, and there has to be profitability associated with it. I don't think anyone after the last round is willing to accept
- 39:52
- Stephanie David: an unprofitable company for the foreseeable future with no real plan for like measurable
- 39:58
- Stephanie David: and relatively quickly getting there to profitability.
- 40:01
- Unidentified speaker (speaker_3): I mean, we're even seeing that like in the in the private markets, right? In different fundraises. I feel like if you used to be a great concept company and you had a lot of growth, that was enough. I'm seeing more and more VCs say, hey, super interesting, not a proven part of your business yet. I will not be funding that component of it. I will
- 40:21
- Unidentified speaker (speaker_3): not be giving you credit for that component of it. But maybe I'll give you money for your existing business that could be slower growing at a much different multiple.
- 40:29
- Stephanie David: Absolutely.
- 40:30
- Unidentified speaker (speaker_2): Yeah.
- 40:31
- Unidentified speaker (speaker_3): Now, when I think about the public markets, I think about, you know, you need to be a certain scale, you need to be profitable. Does that mean that the the VC to public markets pipeline is going to then be a P to public markets pipeline for the foreseeable future?
- 40:47
- Unidentified speaker (speaker_2): It look, I would say um
- 40:50
- Unidentified speaker (UNKNOWN): and
- 40:50
- Unidentified speaker (speaker_2): and you you know, I was listening to some of your podcasts, and you know, even that, as as you guys have talked about, you know, that overlap is becoming more and more right confusing,
- 41:00
- Unidentified speaker (UNKNOWN): right?
- 41:00
- Unidentified speaker (speaker_2): Like where where does the VC spectrum end and where does the growth private equity or pure private equity uh start? I mean, like we've advised companies like um alignment healthcare or um
- 41:15
- Unidentified speaker (UNKNOWN): you
- 41:15
- Unidentified speaker (speaker_2): know, One Medical that had, you know, very large private equity firms that were minority investors in them. And this is in the last go-round. I'm talking about 2019 through 2020 timeframe, right? So so I do believe that the fundamental um elements of the ecosystem in terms of the types of investors might change a
- 41:35
- Unidentified speaker (speaker_2): little bit because um what has definitely changed. you know, in the post-COVID environment is the path to the liquidity event for the VC has gotten a lot longer. And we are seeing some of those compulsions manifest themselves in board discussions that we are part of, right? Where the
- 41:55
- Unidentified speaker (speaker_2): need to go public sooner or the need to drive some kind of a liquidity event sooner um is becoming very much part of the you know the discussion at the board level, you know, particularly with management teams. So what you might see is if this continues to persist, right, particularly in the healthcare tech space where who knows
- 42:15
- Unidentified speaker (speaker_2): when that that market really opens up, right? Like I mean, I'm very enthusiastic about how Hinges performed. You know, our client Omara is kind of hanging in there. So so so you know good signs, but I don't think there is anyone that's, you know, waving a flag saying, hey, just come on, right? I think there's going to be a little while before we see some really high
- 42:35
- Unidentified speaker (speaker_2): quality healthcare tech IPOs. You may see a round of private financing, but there is a clear secondary component where the early stage VCs are are taken out by either a private equity investor or a public. investor, like a crossover.
- 42:53
- Christina Farr: Yeah, I I would agree with that. And I would say that that there also seems to be a little bit of a market education problem. And a lot of that is when you think about companies, for instance, Aura, and we should talk about them. You could have said that was a consumer business, a healthcare business, or a tech business. And I think it's a little bit challenging for a lot of these public
- 43:13
- Christina Farr: markets investors to really understand the category that a lot of these companies are in, especially on the health tech side, where they, you know, you're looking at services a lot, you're sometimes seeing hardware, you're seeing so many different blended go-to-market strategies. You're seeing companies look at the employer market and the payer market, and
- 43:33
- Christina Farr: sometimes also have a consumer aspect to what they're doing. So, do you think that's an issue? where it's like you've got these subscale businesses doing something very different that the market hasn't seen before? You've got analysts in each one of these areas, same thing with journalists in each one of these areas, not crossing all
- 43:53
- Christina Farr: three, and therefore leaving this massive education gap.
- 43:57
- Unidentified speaker (speaker_2): Yeah.
- 43:57
- Stephanie David: So it it's a good chance for us to talk about what we
- 44:02
- Unidentified speaker (UNKNOWN): are
- 44:02
- Stephanie David: uh the approach. we take with a lot of our clients. So you're right. This is like every every company that you used to cover everyone in this space, they're they're all N of One companies. Everyone thinks they are. A lot of them are. They're truly bringing new things
- 44:15
- Unidentified speaker (UNKNOWN): to the tools.
- 44:21
- Unidentified speaker (speaker_3): And uh uh for how AI plays. Yeah.
- 44:23
- Stephanie David: And it'll be some other thing in the future. But all of that is to say what we emphasize to any company that we're working with is education is key and you have to do it early. And you have to hear from a lot of different people in the ecosystem and get feedback and think about what you're
- 44:43
- Stephanie David: actually saying and what you're actually hearing from them. Because you can't tell someone you are a software AI company. when all of your revenue comes from payers. Like it just doesn't work that way. So you need to be honest with yourself. So taking a step back, when we start working with a company
- 45:03
- Stephanie David: that may want to pursue an IPO at some point, 12 to 18 months, sometimes even earlier stage, um, what we tell them is we need to get your story in a public investor ready for
- 45:14
- Unidentified speaker (UNKNOWN): you.
- 45:15
- Stephanie David: format. And then we need to go start seasoning the market, talking to research analysts like yourself, talking to some bankers in the ecosystem, and then some investors who just want to hear stories early, long before they actually have to write a check. And that really helps these companies understand what they are, what they aren't, and what
- 45:35
- Stephanie David: they're going to be able to sell truly to. the market.
- 45:40
- Unidentified speaker (UNKNOWN): And
- 45:40
- Unidentified speaker (speaker_3): crazy. It's crazy to me that some of these folks try to game their subsector.
- 45:45
- Unidentified speaker (UNKNOWN): You
- 45:45
- Stephanie David: can't do it.
- 45:45
- Unidentified speaker (speaker_3): Well
- 45:46
- Unidentified speaker (UNKNOWN): it doesn't
- 45:46
- Stephanie David: work.
- 45:46
- Unidentified speaker (speaker_3): Or if you try it, like I used to think about this when I was marketing with investors, I'd sometimes try to talk about different stocks and they'd say, you know, depending on the Gix classification, like thank you so much, but no. So you could be a software person I'm meeting with and you want to talk about Viva, right? Because that's so close to Salesforce's business model. But I could mention other things in my comp
- 46:07
- Unidentified speaker (speaker_3): sheet that is a Viva comp or saying, oh, you know, we're a technology business. And they say, I just cannot, it's not in my mandate. Yep. Even if
- 46:15
- Unidentified speaker (UNKNOWN): I think
- 46:16
- Unidentified speaker (speaker_3): it's interesting, I'm not buying that stock. So it's kind of a a fool's game to try to do that.
- 46:23
- Unidentified speaker (speaker_2): And you know what's interesting? And and I mean, you guys have talked about it at length. right? Including on recent IPOs. I think the thing that I would like anyone that's listening to this podcast to know that when you go to an investor in particular, especially the investors that we talk to, right, collectively,
- 46:43
- Unidentified speaker (speaker_2): they have a very good pulse on what the company does, where it fits within their ecosystem, be it a mutual fund or a hedge fund.
- 46:51
- Unidentified speaker (speaker_2): and how it's going to be viewed internally. And a number of them have a very good handle on what the valuation framework is going to be like as well. So it's and again, I, you know, I don't begrudge a management team or a board's desire to present themselves in the way that
- 47:11
- Unidentified speaker (speaker_2): they would like to, but they should also be open-minded. about the reality of the system that they're going into, which is these people see companies every day, day in, day out. They have a very good handle on where you're going to fit in. And the more you try to quote unquote game the system, the more kind of red
- 47:30
- Unidentified speaker (UNKNOWN): flags.
- 47:31
- Unidentified speaker (speaker_2): Yeah. Red flags. The more it the red flags come up. Exactly.
- 47:34
- Unidentified speaker (speaker_3): I think it's one of those things. It's like asking one of your children, how do I look? Public markets are very honest. They'll tell you what you are.
- 47:43
- Unidentified speaker (speaker_2): My
- 47:43
- Christina Farr: kids tell me I look nice, Stephanie. You
- 47:45
- Unidentified speaker (UNKNOWN): always
- 47:46
- Unidentified speaker (speaker_3): look nice,
- 47:46
- Christina Farr: Kathy. Sometimes. So what what do you both think are one? Maybe give us one flaw that you see across a lot of healthcare. And I'm gonna go with services because I know it the best. What's the biggest flaw? And I'm happy to share mine, Stephanie. Obviously, you want to hear yours. And then what's the biggest? like great thing that you think is not being
- 48:06
- Christina Farr: recognized enough by the public markets? Um, I have definitely have my flaw. I think my flaw is oftentimes there is way too much revenue wrapped up in a single customer. Um big problem across the board with a lot of these companies where when they go out and you look at the materials, it's like, oh wow, okay.
- 48:26
- Unidentified speaker (UNKNOWN): A
- 48:26
- Christina Farr: huge reliance.
- 48:27
- Christina Farr: on a single payer.
- 48:29
- Unidentified speaker (UNKNOWN): Accolade.
- 48:30
- Christina Farr: Accolade, I think that was a story with Omada as well. I mean it's also a story with one medical, there's
- 48:35
- Unidentified speaker (UNKNOWN): the
- 48:35
- Christina Farr: list goes on and on and on. But you could believe over time, of course, that this is a a stepping stone and they will eventually diversify more and more and many of these businesses have to their credit. But I think that's one that I see consistently. Um, And then maybe I'll give my what I think is good about the companies and then see if you all agree. Um,
- 48:55
- Christina Farr: I actually love the fact that so many of them are real services. I think it's
- 48:59
- Unidentified speaker (UNKNOWN): really
- 49:00
- Christina Farr: powerful to actually have a say in the way that patient care is being administered. And I think this is honestly, as a patient, some of the highest quality care that you can get. And sometimes I see that being underemphasized, especially if brick and mortar is involved in any way, um, to tell the A st AI story, to tell the the
- 49:20
- Christina Farr: tech story. And I wish we could spend more time telling the patient story.
- 49:24
- Unidentified speaker (UNKNOWN): What
- 49:24
- Christina Farr: what do you both think?
- 49:25
- Unidentified speaker (speaker_2): I mean maybe I'll start with uh with the floor and and Stephanie's very
- 49:31
- Christina Farr: Stephanie's got floors.
- 49:32
- Unidentified speaker (UNKNOWN): Yeah, yeah. I mean look at it. Not as cross a person, end, but
- 49:34
- Stephanie David: obviously
- 49:36
- Unidentified speaker (speaker_2): I'll start
- 49:37
- Unidentified speaker (UNKNOWN): with
- 49:37
- Unidentified speaker (speaker_2): the obvious floor. You know, Jordan's the the domain expert here, so I'm gonna throw her the tougher question. Look, the the one floor in I would say the broader services space that I think caught everybody off guard, obviously the investors, to some extent the analysts, but particularly the management teams, surprisingly, was utilization, right?
- 49:56
- Unidentified speaker (UNKNOWN): Oh, that's
- 49:57
- Christina Farr: a good one.
- 49:57
- Unidentified speaker (speaker_2): In the Medicare Advantage space in particular, right? Where
- 50:02
- Unidentified speaker (UNKNOWN): I mean
- 50:02
- Unidentified speaker (speaker_2): I won't name names, but there are instances of companies that gave guidance and within a matter of weeks, not months, had to restate that guidance, right? Because the utilization caught them off guard. So I would say one of the things, and and maybe look, this is where I think I'll rely a lot on Jordan Gordon and her partner Asher,
- 50:22
- Unidentified speaker (speaker_2): right? These guys are real domain experts. But I always am like the squeaky. wheel that'll bring up the utilization question. And it's only when one of them tells me that's not relevant here that I shut up.
- 50:33
- Unidentified speaker (UNKNOWN): Right.
- 50:33
- Unidentified speaker (speaker_2): But for me, like the the concept of utilization and the the negative surprise that it could bring on a services story is a huge floor, right?
- 50:43
- Unidentified speaker (UNKNOWN): Should we should
- 50:44
- Christina Farr: we and should we do floors first Fast or
- 50:45
- Unidentified speaker (UNKNOWN): you want to do your pro
- 50:46
- Christina Farr: your pro?
- 50:46
- Stephanie David: Okay.
- 50:47
- Unidentified speaker (speaker_2): Please.
- 50:47
- Stephanie David: Um so I'm gonna go a little bit more on a uh like
- 50:52
- Stephanie David: storytelling side of things. So I
- 50:55
- Unidentified speaker (UNKNOWN): I
- 50:55
- Stephanie David: think a flaw is when a company either is way too narrow, like point solutions aren't the answer. Nobody, nobody's gonna want those, honestly, anymore. Like that was a time of the past. But then because
- 51:10
- Stephanie David: of this like uh allergic reaction to point solutions, I think people swing swung way too far to the other side and we're like, I can do everything. My TAM is the biggest TAM on the planet, and we're gonna go in all of these different directions. And it's just like the lack of focus when people get too excited about the problem they're solving. Um, we worked with a public company because a lot of my
- 51:30
- Stephanie David: work is not just on the private side, but also with public companies um
- 51:34
- Stephanie David: on their investor relations, and and they had 14 growth avenues. and we were like that's not
- 51:41
- Unidentified speaker (UNKNOWN): gonna work
- 51:42
- Unidentified speaker (UNKNOWN): if you've got
- 51:43
- Unidentified speaker (speaker_3): 14 growth avenues you have none
- 51:45
- Unidentified speaker (UNKNOWN): none
- 51:45
- Stephanie David: exactly so so just like being honest to what you are and then focusing and like understanding the actual path to growth
- 51:55
- Unidentified speaker (speaker_3): I have so many flaws
- 51:57
- Unidentified speaker (UNKNOWN): I'm sorry,
- 51:57
- Christina Farr: Stephanie just
- 51:59
- Unidentified speaker (UNKNOWN): like
- 51:59
- Unidentified speaker (speaker_2): booking
- 51:59
- Unidentified speaker (UNKNOWN): the a board
- 52:00
- Unidentified speaker (speaker_3): let me let me let me just give you like some quick hits of things I used to do to management teams for me to just like initially evaluate it. Cause I think the management team is the most important part of the business, not even the business model, it's the management team. So did you tell me what your business did in one sentence? No. If I don't know your business model in one sentence, that's not a good business model. I'm out.
- 52:20
- Unidentified speaker (speaker_3): Um, could you could you get pushback and get that feedback and kind of understand, hey, that's a concern I have about the business. model and do it in a reasonable way and explain it to me? Great. Can you not? Can you get defensive? You're gonna hate the public markets, buddy. We're not gonna have a good time here. Um hey, here is a tail risk. Here's something
- 52:40
- Unidentified speaker (speaker_3): really scary that could happen. Have you thought of it? Are you scared of it? Have you planned for it? If not, right, are you are you giving me the we have 15 other avenues for growth? No, you don't. Out.
- 52:51
- Unidentified speaker (speaker_2): And the one that we always talk about, you know, going back to your analyst days, how do you make money?
- 52:57
- Unidentified speaker (speaker_2): It's the most simple and innocuous question, but the one that a lot of management teams trip over.
- 53:03
- Christina Farr: And that's where we get the jogging.
- 53:05
- Unidentified speaker (speaker_2): Yeah.
- 53:05
- Unidentified speaker (UNKNOWN): Every initiation, you
- 53:07
- Christina Farr: you know, like
- 53:08
- Unidentified speaker (UNKNOWN): everything I wrote
- 53:09
- Christina Farr: form jogging. jargon.
- 53:10
- Unidentified speaker (speaker_3): Every initiation, first thing, how do they make money? And it it's like, hey, we are a AI native of no. Who's paying you? Why are they paying you? Are they happy they paid
- 53:21
- Unidentified speaker (UNKNOWN): you? What
- 53:22
- Stephanie David: when we work with companies, a lot of the time it's on investor presentations. Just like they're they're not good a lot of the time. And we will make companies go through the exercise of like, if we made a slide that was titled How We Make Money, what would it look
- 53:36
- Unidentified speaker (UNKNOWN): like?
- 53:36
- Stephanie David: And
- 53:36
- Unidentified speaker (UNKNOWN): like it has to
- 53:37
- Stephanie David: all fit on this slide. And it can't be a whole encyclopedia. And it's like a lot of times doesn't get used. We don't need it, but the exercise is helpful. Yeah,
- 53:46
- Unidentified speaker (speaker_3): important.
- 53:47
- Christina Farr: Okay, so now we have to flip to the positive. I already shared mine. What about
- 53:50
- Unidentified speaker (UNKNOWN): you?
- 53:51
- Unidentified speaker (speaker_2): So here's what I am amazingly enthusiastic about is what I call the specialized value-based care space. Um, and what I mean by that is
- 54:02
- Unidentified speaker (UNKNOWN): companies.
- 54:03
- Unidentified speaker (speaker_2): that have identified specific needs, right? I'll I'll give you a couple of, I mean, the the company that you'll be talking to today is a case in point, right? Like they have identified a specific niche for
- 54:17
- Unidentified speaker (speaker_2): patients that are almost at end of life, that, you know, as Kush describes it, you know, frequent flyers, right? Um, like why do they need to go to the ER? Right? What is the cost of the system of like an average 80-year-old who's alone at home, doesn't have any
- 54:36
- Unidentified speaker (speaker_2): caregivers, having to call 911 to go to like imagine what it, what a, what a space that was ripe for disruption. The other company that we, you know, Jordan and I and our team have spent a lot of time around is Monogram Health. another case in point, right? Where the idea, it's probably not as old as the maybe the Ennoble,
- 54:56
- Unidentified speaker (speaker_2): you know, demographic, but getting there. But the idea there is the average senior takes about 12 to 14 medications and sees about seven to nine specialists. And imagine that senior having to go from place to place. And imagine being able to do that. by bringing the specialist to their
- 55:16
- Unidentified speaker (speaker_2): house. Right. So I'm just very enthusiastic about entrepreneurs and in a lot of cases, like medical professionals, like uh like at Monogram, that have identified this niche and are bringing specialized value-based care. So I knew I know VBC was a full four-letter letter word for a period of time. I think the next
- 55:36
- Unidentified speaker (speaker_2): iteration of VBC is going to be very dynamic.
- 55:40
- Stephanie David: Um, all right. The best thing I think about these companies, and this goes back like a thousand years when I started working at our predecessor Westwick, now ICR, um, and we kind of like divided the associates up between where was their focus area gonna be. Um, what I've loved most and what drew me to this space was
- 56:00
- Stephanie David: it's such a tangible, like solving problem. problems that are in my everyday life. Um, so a company where they tell me their story, and I'm like, oh my God, I could have used that. That's my favorite part about any of these companies. Um, we had the opportunity to meet and uh learn a lot about MIDI uh recently from
- 56:20
- Stephanie David: Joanna. And I described an issue I had had coming out of the uh after I had my first child. before my second. And she was like, we could have helped you with that. And I was like, that that's why these companies are so great. People are finding problems that we all deal with and fixing them.
- 56:36
- Christina Farr: And by the way, uh that business, I think, underestimated in how much of the growth has been organic. Yeah. Literally just word of mouth. It's just women
- 56:45
- Unidentified speaker (UNKNOWN): You're talking
- 56:45
- Christina Farr: to other women.
- 56:46
- Stephanie David: At at uh our Halloween, like pre-get together before we went trick-or-treating, my neighbor was. like, So I got other issues. What do I do? And I was like, do a mini visit. It's gonna solve exactly what you need.
- 56:58
- Unidentified speaker (speaker_3): So big. It's so big for women.
- 57:00
- Unidentified speaker (UNKNOWN): Now,
- 57:00
- Unidentified speaker (speaker_3): here's what I would say, which is a little I don't look for a specific part of the business model. I don't look for something specific in, you know, how the business is being run today, because there's trends they that come and go, right? Value Value-based based care, digital health, um, AI right now. We'll see what happens for all. of them. I love a anti-fragile moment from the
- 57:19
- Unidentified speaker (UNKNOWN): founder.
- 57:20
- Unidentified speaker (speaker_3): You know, something that got stronger because there was a break in the business. I think about Athena Health, they started as an entirely different business model.
- 57:28
- Christina Farr: They were
- 57:28
- Unidentified speaker (UNKNOWN): in women's
- 57:29
- Christina Farr: health, I think initially.
- 57:30
- Unidentified speaker (speaker_3): They were a women's health care provider.
- 57:32
- Unidentified speaker (UNKNOWN): And then
- 57:33
- Unidentified speaker (speaker_3): yes, yes. And then they built this EHR and it was fantastic. And then we leaned get into it and just kind of seeing the management team has listened to the market, has been able to iterate, has been able to go through a tough time already and come out stronger. That tells me so much more of how you're going to function five years, 10 years from now as a public company, versus how you're going to do
- 57:53
- Unidentified speaker (speaker_3): three months after the IPO.
- 57:55
- Unidentified speaker (speaker_2): Yep. Yep.
- 57:56
- Christina Farr: I would agree with that. Um Jordan, Samir, thank you so much for being here. We could have
- 58:01
- Unidentified speaker (UNKNOWN): talked to you
- 58:01
- Christina Farr: for another like hour, I feel like. just trading some of these war stories from over the years. Um, and to our viewers, if you'd like to learn more about ICR Healthcare, you can find more about this team in the show notes.
- 58:13
- Unidentified speaker (speaker_3): That's a wrap from the season to premiere. Thank you so much for joining. And hopefully we'll see a lot more of you guys out in the markets.
- 58:19
- Unidentified speaker (speaker_2): Thank you. Thank you for having
- 58:20
- Unidentified speaker (UNKNOWN): us.
- 58:21
- Stephanie David: Thank you.
- 58:21
- Unidentified speaker (UNKNOWN): Thank
- 58:22
- Unidentified speaker (speaker_3): you to ICR Healthcare for sponsoring this episode, and thank you to Butterfly Network, who is our sponsor for. the whole season.